MedPageToday The vaccine appeared to prompt responses to a range of H5N1 clades. An intranasal adjuvanted recombinant influenza vaccine appeared to safely prompt a robust response to a range of H5N1 clades, according to a phase I trial.
Immune responses among the three groups that received one of three doses of the adjuvanted clade 2.1 influenza A/H5 recombinant hemagglutinin glycoprotein (rH5) vaccine were improved from baseline and they were better than those in comparator groups who received an unadjuvanted vaccine or placebo, reported Justin R. Ortiz, MD, of the Center for Vaccine Development and Global Health at the University of Maryland in Baltimore, and colleagues in Nature Communicationsopens in a new tab or window.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.